Predict your next investment

HEALTHCARE | Drug Development
oncoimmune.com

See what CB Insights has to offer

Business Relationships

1

OncoImmune Partners & Customers

1 Partners and customers

OncoImmune has 1 strategic partners and customers. OncoImmune recently partnered with Pfizer on September 9, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

9/15/2016

Licensee

Pfizer

United States

PFIZER REPORTS THIRD-QUARTER 2016 RESULTS

In September 2016 , Pfizer Inc. entered into an exclusive option and license agreement with OncoImmune , Inc. for ONC-392 , a novel , potentially differentiated preclinical anti-CTLA4 monoclonal antibody in a deal worth up to $ 250 million in upfront and potential milestone payments .

3

Date

9/15/2016

Type

Licensee

Business Partner

Pfizer

Country

United States

News Snippet

PFIZER REPORTS THIRD-QUARTER 2016 RESULTS

In September 2016 , Pfizer Inc. entered into an exclusive option and license agreement with OncoImmune , Inc. for ONC-392 , a novel , potentially differentiated preclinical anti-CTLA4 monoclonal antibody in a deal worth up to $ 250 million in upfront and potential milestone payments .

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.